PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/583,785 **TRANSMITTAL** Filing Date June 19, 2006 FORM JUL 1 6 2007 First Named Inventor Seeger et al. Art Unit 4411 Examiner Name tbA (to be used for all correspondence after initial filing) **Attorney Docket Number** 607927-000001 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a **Proprietary Information** After Final **Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) **Status Letter** Change of Correspondence Address Other Enclosure(s) (please Identify Extension of Time Request Terminal Disclaimer below): 1. Submission of Substitute Sequence Request for Refund **Express Abandonment Request** Listing Under 37 C.F.R. 1.821 2. Diskette Sequence Listing CD, Number of CD(s) _ Information Disclosure Statement 3. Paper Sequence 2. Return Receipt Postcard Landscape Table on CD **Certified Copy of Priority** Remarks Document(s) Also encliosed is a copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Thelen Reid Brown Raysman & Steiner LLP (Customer Number 29858) Signature Printed name James P. Demers Date Reg. No. July 10, 2007 34,320 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature enver

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James P

Typed or printed name

Demers

Date

July 10, 2007

Box



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Seeger et al.

Docket No.:

607927-000001

Application. No.:

10/583,785

Examiner:

tba

Filed:

June 19,2006

Group Art Unit:

4411

Title:

NOVEL CHIMERIC PLASMINOGEN ACTIVATORS AND THEIR

PHARMACEUTICAL USE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING UNDER 37 C.F.R. §1.821 Sir:

This is in response to the RAW SEQUENCE LISTING ERROR REPORT produced by the STIC on May 7, 2007. Enclosed is a diskette containing a substitute sequence listing in connection with this application, and a printed copy of the sequence listing.

The undersigned hereby states, in accordance with 37 C.F.R. §1.821(f), that the sequence information submitted in computer-readable form is identical to the written sequence listing submitted on paper. The undersigned further states that the submission herein, filed in accordance with 37 C.F.R. §1.821(g), does not include new matter.

The Commissioner is hereby authorized to charge any fees, which may be required or credit any overpayment to the undersigned attorney's Deposit Account No. 02-4270, with reference to Attorney Docket No. 607927-000001.

Respectfully submitted,

Thelen Reid Brown Raysman & Steiner, LLP

James P. Demers, Reg. No. 34,320

Thelen Reid Brown Raysman & Steiner LLP

900 Third Avenue

New York, NY 10022

Tel: 212-895-2000

UNITED STATES DEPARTMENT OF COMMERCE United States Potent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED APPLICANT ATTY. DOCKET NO. U.S. APPLICATION NUMBER NO. 7927-01US Werner Seeger-10/583,785 INTERNATIONAL APPLICATION NO. 3 0 2007 Docket Date MAY PCT/EP03/14542 PRIORITY DATE I.A. FILING DATE 29858 THELEN REID BROWN RAYSMAN & TEINER 12/18/2003 Attorney(s): MB 900 THIRD AVENUE NEW YORK, NY 10022 **CONFIRMATION NO. 4411** Action: 371 FORMALITIES LETTER Action Date: _ *QC000000023978848* Final: Initials: Date Mailed: 05/22/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE, within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/583,785	PCT/EP03/14542	7927-01US

FORM PCT/DO/EO/922 (371 Formalities Notice)